Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5962865 | 0.88 | MAPT (0.51) | MAPTNPC1MAPK1HTTMAPK13 | |
| SCHEMBL11753699 | 0.87 | TSHR (0.51) | HTTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL538169 | 0.85 | GAA (0.59) | MAPTMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9717019 | 0.84 | MAPK13 (0.55) | MAPTNPC1MAPK1HTTMAPK13 | |
| SCHEMBL11756227 | 0.83 | MAPK13 (0.53) | NPC1HTTMAPK13MAPK12MAPK11 | |
| SCHEMBL31696155 | 0.83 | MAPT (0.63) | MAPTNPC1MAPK1HTTMAPK13 | |
| SCHEMBL3520933 | 0.83 | RECQL (0.71) | NPC1MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL2704094 | 0.83 | MAPT (0.54) | MAPTNPC1MAPK1HTTRECQL | |
| SCHEMBL9654244 | 0.83 | RECQL (0.71) | MAPTNPC1MAPK1HTTMAPK13 | |
| SCHEMBL11756492 | 0.82 | CSNK2A1 (0.56) | MAPTNPC1HTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2014-12-04 | — | — | US | disclosed |
| US-8722669-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2014-05-13 | — | — | US | disclosed |
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-11-22 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295895-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, NR2E3, LRAT | MAPT 755/4885NPC1 29/4885MAPK1 4633/4885 |
| US-20140357611-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TYR, HRH2 | MAPT 640/4885NPC1 80/4885MAPK1 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.